Ximelagatran, the new oral anticoagulant: Would warfarin survive the challenge?

Cardiovascular Drug Reviews

Volumn 23, Issue 4, 2005, Pages 331-344

  Mousa, Shaker A ^a,c,d   Abdel Razeq, Hikmat N ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b KING HUSSEIN CANCER CENTER   (Jordan)

^c Department of Pharmacology ^*  (United States)

^d Pharmaceutical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; BILIRUBIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY THROMBOSIS; BINDING AFFINITY; BLEEDING; CLINICAL TRIAL; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG TRANSFORMATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; SURVIVAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 33744953928     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2005.tb00176.x     Document Type: Review

References (50)

1. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119(Suppl 1):22S-38S.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994;308:235-246.
3. Bratzler DW, Raskob FE, Murray CK, Bumpus LJ, Piatt DS. Underuse of VTE prophylaxis for general surgery patients: Physician practices in the community hospital setting. Arch Intern Med 1998;158: 1909-1912.
4. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 2003;31:645-651.
5. Colwell CW, Berkowitz SD, Comp PC, et al. for EXULT B Investigators Orthopaedic Surgery. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B [abstract]. Blood 2003;102:14a.
6. Colwell CW Jr, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: A randomised, double-blind study. J Thromb Haemost 2003;1:2119-2130.
7. Cullberg M, Eriksson UG, Wahlander K, Eriksson H, Schulman S, Karlsson MO. Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther 2005; 77(4):279-90.
8. Eriksson BI, Agnelli G, Cohen AT, et al.; EXPRESS Study Group. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: The EXPRESS study. J Thromb Haemost 2003;1:2490-2496.
9. Eriksson BI, Agnelli G Cohen AT, et al.; METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296.
10. Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294-305.
11. Eriksson BI, Ekman S, Kälebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996;347: 635-639.
12. Eriksson UG, Johanesson S, Attman PO, Frison L, Fager G Samuelsson O. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003;42:743-753.
13. Exanta (ximelagatran) tablets NDA 21-686. FDA Advisory Committee Briefing Document. Cardiovascular and Renal Drugs Advisory Committee. 10 September 2004. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_01_AstraZeneca- Backgrounder.pdf.
14. Francis CW, Berkowitz SD, Comp PC, et al.; EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349:1703-1712.
15. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran vs. warfarin for the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind trial. Ann Intern Med 2002;137: 648-655.
16. Francis CW, Ginsberg JS, Berkowitz SD, Bounameaux H, Davidson BL, Eriksson H, for the THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism [Abstract]. Blood 2003;102:6a.
17. Friedman R, Gallus A, Cushner F, FitzGerald G, Anderson F, for the GLORY Investigators Compliance with ACCP Guidelines for Prevention of Venous Thromboembolism. Multinational findings from the Global Orthopedic Registry (GLORY) [abstract]. Blood 2003;102:165a.
18. Gillies TE, Ruckley CV, Nixon SJ. Still missing the boat with fatal pulmonary embolism. Br J Surg 1996;83: 1394-1395.
19. Greets WH, Heit AD, Clagett GP, et al. Prevention of venous thromboembolism: sixth ACCP Consensus Conference on antithrombotic therapy. Chest 2001;119:132s-175s.
20. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;70:110-118.
21. Gustafsson D, Nyström J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181.
22. Haas S. Oral direct thrombin inhibition: An effective and novel approach for venous thromboembolism. Drugs 2004;64(Suppl 1):7-16.
23. Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-438.
24. Hankey GJ, Klijn CJ, Eikelboom JW. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation? Stroke 2004;35:389-391.
25. Hart RG. Atrial fibrillation and stroke prevention. N Engl J Med 2003;349:1015-1016.
26. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.
27. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. Eur J Clin Pharmacol 2002;57:751-758.
28. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase 2 dose-finding study. Arch Intern Med 2001;161:2215-2221.
29. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(Suppl 1):8S-21S.
30. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119(Suppl 1):64S-94S.
31. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
32. Hylek EM, Skates SJ, Sheehan MA, Singer DE, An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
33. Johanson LC, Nystrom P, Johnsson G et al. No clinically relevant effect of food or repeated dosing on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young, healthy Japanese males. Pathophysiol Haemost Thromb 2002;32(Suppl 2):130.
34. Kaplan KL, Francis CW. Direct thrombin inhibitors. Semin Hematol 2002;39:187-196.
35. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: The ximelagatran experience. J Am Coll Cardiol 2005;46(11):1986-1995.
36. Kniffin WD, Baron JA, Barret J, Birkmeyer JD, Anderson FA. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861-866.
37. Merli G, Spiro TE, Olssen CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134: 191-202.
38. Mohr DN, Silverstein MD, Ilstrup DM, Heit JA, Morrey BF. VTE associated with hip and knee arthroplasty: Current prophylactic practices and outcomes. Mayo Clin Proc 1992;67:861-870.
39. Nutescu E, Racine E. Traditional vs. modern anticoagulant strategies: summary of the literature. Am J Health Syst Pharm 2002;59:S7-S14.
40. Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003;362:1691-1698.
41. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355: 1295-1302.
42. Reiffel JA. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation? Curr Opin Cardiol 2004;19:58-63.
43. Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: Prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). Br Med J 1992;305;1460-1465.
44. Sarich TC, Schultzer KM, Wollbratt M, Wall U, Kessler E, Eriksson UG. No pharmacokinetic or pharmaco-dynamic interaction between digoxin and ximelagatran, an oral direct thrombin inhibitor [abstract]. Blood 2003;102;127b.
45. Schulman S, Wahlander K, Lundström T, Clason SB, Eriksson H, for the THRIVE III Investigators, Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721.
46. Warfarin [package insert]. Pomona, NY: Barr Laboratories, 2002.
47. Weitz J, Orally active direct thrombin inhibitors. Semin Vasc Med 2003;3(2):131-138.
48. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study, Stroke 1991;22;983-988.
49. Wolzt M, Sarich TS, Eriksson UG. Pharmacokinetics and pharmacodynamics of ximelagatran. Semin Vasc Med 2005;5(3):245-253.
50. Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999;3(3):433-64.